Andreas Sashegyi

Andreas Sashegyi

UNVERIFIED PROFILE

Are you Andreas Sashegyi?   Register this Author

Register author
Andreas Sashegyi

Andreas Sashegyi

Publications by authors named "Andreas Sashegyi"

Are you Andreas Sashegyi?   Register this Author

21Publications

651Reads

41Profile Views

On the Interpretation of the Hazard Ratio and Communication of Survival Benefit.

Oncologist 2017 04 17;22(4):484-486. Epub 2017 Mar 17.

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388384PMC
April 2017

Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.

J Chemother 2017 Feb 6;29(1):62-64. Epub 2016 Feb 6.

b Eli Lilly and Company , Bridgewater , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1120009X.2015.1113023DOI Listing
February 2017

Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.

Nat Rev Drug Discov 2014 Aug;13(8):638-40

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3681-c1DOI Listing
August 2014

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

J Crit Care 2007 Jun 31;22(2):142-52. Epub 2007 Jan 31.

Department of Critical Care Medicine, Hôpital St Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcrc.2006.09.007DOI Listing
June 2007

Predictive probability of success and the assessment of futility in large outcomes trials.

J Biopharm Stat 2007 ;17(1):45-63

Eli Lilly and Company, Lilly Corporate Center, DC 6072, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10543400601001485DOI Listing
February 2007

Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.

Curr Med Res Opin 2005 Jan;21(1):135-40

Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079904x18045DOI Listing
January 2005

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

J Bone Miner Res 2004 Aug 12;19(8):1270-5. Epub 2004 Apr 12.

Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, California 92093-0607, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1359/JBMR.040406DOI Listing
August 2004

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

JAMA 2002 Feb;287(7):847-57

Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego School of Medicine, 9500 Gilman Dr, No. 0607, La Jolla, CA 92093-0607, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.287.7.847DOI Listing
February 2002